175 related articles for article (PubMed ID: 32520005)
1. [Theranostics in 2020: Neuroendocrine tumors].
Sipka G; Besenyi Z; Farkas I; Pávics L
Magy Onkol; 2020 Jun; 64(2):119-130. PubMed ID: 32520005
[TBL] [Abstract][Full Text] [Related]
2. Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine.
Arora G; Bandopadhyaya G
Ann Nucl Med; 2018 Apr; 32(3):151-164. PubMed ID: 29374820
[TBL] [Abstract][Full Text] [Related]
3. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
4. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.
Pencharz D; Gnanasegaran G; Navalkissoor S
Br J Radiol; 2018 Nov; 91(1091):20180108. PubMed ID: 30102557
[TBL] [Abstract][Full Text] [Related]
5. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
6. Molecular Imaging and Theranostics in Pancreatic Neuroendocrine Tumours: From a Luminous Present to an Even Brighter Future.
Paola M; Mansi L
Curr Radiopharm; 2019; 12(2):93-95. PubMed ID: 31362647
[No Abstract] [Full Text] [Related]
7. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
8. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
9. "Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.
Ehlerding EB; Lan X; Cai W
Theranostics; 2018; 8(3):812-814. PubMed ID: 29344308
[TBL] [Abstract][Full Text] [Related]
10. Theranostic radiopharmaceuticals: established agents in current use.
Ballinger JR
Br J Radiol; 2018 Nov; 91(1091):20170969. PubMed ID: 29474096
[TBL] [Abstract][Full Text] [Related]
11. Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine.
Levine R; Krenning EP
J Nucl Med; 2017 Sep; 58(Suppl 2):3S-9S. PubMed ID: 28864612
[TBL] [Abstract][Full Text] [Related]
12. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies.
Agrawal A; Rangarajan V; Shah S; Puranik A; Purandare N
Br J Radiol; 2018 Nov; 91(1091):20180103. PubMed ID: 30048149
[TBL] [Abstract][Full Text] [Related]
13. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
14. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
15. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors: current recommendations for diagnosis and surgical management.
Joseph S; Wang YZ; Boudreaux JP; Anthony LB; Campeau R; Raines D; O'Dorisio T; Go VL; Vinik AI; Cundiff J; Woltering EA
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):205-31, x. PubMed ID: 21349420
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
18.
Hicks RJ; Jackson P; Kong G; Ware RE; Hofman MS; Pattison DA; Akhurst TA; Drummond E; Roselt P; Callahan J; Price R; Jeffery CM; Hong E; Noonan W; Herschtal A; Hicks LJ; Hedt A; Harris M; Paterson BM; Donnelly PS
J Nucl Med; 2019 Jun; 60(6):777-785. PubMed ID: 30442752
[TBL] [Abstract][Full Text] [Related]
19. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
20. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach.
Werner RA; Bluemel C; Lassmann M; Kudlich T; Higuchi T; Lopci E; Allen-Auerbach M; Colletti PM; Rubello D; Zatelli MC; Herrmann K
Clin Nucl Med; 2015 May; 40(5):e271-7. PubMed ID: 25642915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]